同型半胱氨酸与ACS患者预后的关系研究的进展  

Research progress of relationship between homocysteine and prognosis in ACS patients

作　　者：张虹 寇俊杰[1] ZHANG Hong;KOU Jun-jie(Department of Cardiology,Second Affiliated Hospital of Harbin Medical University,Harbin,Heilongjiang,150081,China)

机构地区：[1]哈尔滨医科大学附属第二医院心内科,黑龙江哈尔滨150081

出　　处：《心血管康复医学杂志》2023年第2期211-214,共4页Chinese Journal of Cardiovascular Rehabilitation Medicine

摘　　要：同型半胱氨酸(Hcy)通过一系列机制导致急性冠脉综合征(ACS)的发生,且Hcy水平与冠脉病变程度呈正相关。此外,Hcy可促进支架内再狭窄及非梗死相关血管的病变进展,导致ACS患者行经皮冠状动脉介入治疗术后预后不佳。本文就Hcy与ACS患者预后的关系研究的进展作一综述,旨在为ACS患者的治疗与预后提供参考。Homocysteine(Hcy)leads to occurrence of acute coronary syndrome(ACS)via a series of mechanisms.And Hcy level is positively correlated with severity of coronary artery disease.In addition,Hcy can promote progression of in-stent restenosis and non-infarct-related vessel lesions,leading to poor prognosis in ACS patients after percutaneous coronary intervention.The present article makes a review on relationship between Hcy and prognosis in ACS patients,aiming at providing reference for the treatment and prognosis of ACS patients.

关 键 词：急性冠状动脉综合征 血管成形术 气囊 冠状动脉 高半胱氨酸 

分 类 号：R541.4[医药卫生—心血管疾病]